Literature DB >> 7686212

Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses.

G T Miller1, P S Hochman, W Meier, R Tizard, S A Bixler, M D Rosa, B P Wallner.   

Abstract

Accessory cell surface molecules, such as T cell antigen CD2 and its ligand lymphocyte function-associated antigen 3 (LFA-3; CD58), are critical costimulatory pathways for optimal T cell activation in response to antigens. Interaction of CD2 with cell surface LFA-3 not only increases T cell/accessory cell adhesion, but also induces signal transduction events involved in the regulation of T cell responses. In this report, we show that specific interactions of LFA-3 with CD2 can result in T cell unresponsiveness to antigenic or mitogenic stimuli in vitro. By deletion of certain regions of the extracellular domain of LFA-3, we localized the CD2 binding site to the first domain of LFA-3. We then demonstrated that a soluble, purified first domain-LFA-3/IgG1 fusion protein (LFA3TIP) interacts with CD2 and binds to the same CD2 epitope as purified multimeric or cell surface-expressed LFA-3. LFA3TIP inhibits tetanus toxoid, hepatitis B surface antigen, anti-CD3 mAb, Con A, and phytohemagglutinin P-induced T cell proliferation, as well as xenogeneic and allogeneic mixed lymphocyte reactions (MLR). Unlike anti-LFA-3 or anti-CD2 monoclonal antibodies (mAbs) which inhibit T cell responses by blocking LFA-3/CD2 binding, LFA3TIP is capable of rendering T cells unresponsive to antigenic stimuli in situations where T cell activation is independent of CD2/LFA-3 interactions. Furthermore, LFA3TIP, but not blocking anti-CD2 mAbs, is capable of inducing T cell unresponsiveness to secondary stimulation in allogeneic MLR. This inhibition of T cell responses by LFA3TIP occurs through a different mechanism from that of mAbs to LFA-3 or CD2.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686212      PMCID: PMC2191085          DOI: 10.1084/jem.178.1.211

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  32 in total

1.  Introduction of stable high-copy-number DNA into Chinese hamster ovary cells by electroporation.

Authors:  J Barsoum
Journal:  DNA Cell Biol       Date:  1990-05       Impact factor: 3.311

2.  CD2-mediated adhesion facilitates T lymphocyte antigen recognition function.

Authors:  P Moingeon; H C Chang; B P Wallner; C Stebbins; A Z Frey; E L Reinherz
Journal:  Nature       Date:  1989-05-25       Impact factor: 49.962

3.  Enhancement of LFA-1-mediated cell adhesion by triggering through CD2 or CD3 on T lymphocytes.

Authors:  Y van Kooyk; P van de Wiel-van Kemenade; P Weder; T W Kuijpers; C G Figdor
Journal:  Nature       Date:  1989-12-14       Impact factor: 49.962

4.  The role of CD2/LFA-3 interaction in antigen- and mitogen-induced activation of human T cells.

Authors:  G Tiefenthaler; T Hünig
Journal:  Int Immunol       Date:  1989       Impact factor: 4.823

5.  Increases in tyrosine phosphorylation are detectable before phospholipase C activation after T cell receptor stimulation.

Authors:  C H June; M C Fletcher; J A Ledbetter; L E Samelson
Journal:  J Immunol       Date:  1990-03-01       Impact factor: 5.422

6.  Role of interaction of CD2 molecules with lymphocyte function-associated antigen 3 in T-cell recognition of nominal antigen.

Authors:  S Koyasu; T Lawton; D Novick; M A Recny; R F Siliciano; B P Wallner; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

7.  LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release.

Authors:  D S Webb; Y Shimizu; G A Van Seventer; S Shaw; T L Gerrard
Journal:  Science       Date:  1990-09-14       Impact factor: 47.728

8.  The CD2 ligand LFA-3 activates T cells but depends on the expression and function of the antigen receptor.

Authors:  L K Bockenstedt; M A Goldsmith; M Dustin; D Olive; T A Springer; A Weiss
Journal:  J Immunol       Date:  1988-09-15       Impact factor: 5.422

9.  CD45 regulates signal transduction and lymphocyte activation by specific association with receptor molecules on T or B cells.

Authors:  J A Ledbetter; N K Tonks; E H Fischer; E A Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

10.  Interdependence of CD3-Ti and CD2 activation pathways in human T lymphocytes.

Authors:  A Alcover; C Alberini; O Acuto; L K Clayton; C Transy; G C Spagnoli; P Moingeon; P Lopez; E L Reinherz
Journal:  EMBO J       Date:  1988-07       Impact factor: 11.598

View more
  45 in total

1.  Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters.

Authors:  Q Wang; Y Wang; D M Hyde; P J Gotwals; V E Koteliansky; S T Ryan; S N Giri
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

2.  Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression.

Authors:  D J Lo; T A Weaver; L Stempora; A K Mehta; M L Ford; C P Larsen; A D Kirk
Journal:  Am J Transplant       Date:  2010-11-10       Impact factor: 8.086

Review 3.  Targeting memory T cells in type 1 diabetes.

Authors:  Mario R Ehlers; Mark R Rigby
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

4.  Development and application of a real-time PCR method for pharmacokinetic and biodistribution studies of recombinant adenovirus.

Authors:  Xian-Xing Xu; Xue Shui; Zhi-Hang Chen; Cheng-Qi Shan; Yu-Nan Hou; Yuan-Guo Cheng
Journal:  Mol Biotechnol       Date:  2009-05-06       Impact factor: 2.695

5.  Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration.

Authors:  Ashay K Vaishnaw; Christopher N TenHoor
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-12       Impact factor: 2.745

Review 6.  Advances in immunosuppression for renal transplantation.

Authors:  Antoine Durrbach; Helene Francois; Severine Beaudreuil; Antoine Jacquet; Bernard Charpentier
Journal:  Nat Rev Nephrol       Date:  2010-02-02       Impact factor: 28.314

7.  Peyer's patches are required for oral tolerance to proteins.

Authors:  K Fujihashi; T Dohi; P D Rennert; M Yamamoto; T Koga; H Kiyono; J R McGhee
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

Review 8.  Restoring Regulatory T Cells in Type 1 Diabetes.

Authors:  Allyson Spence; Qizhi Tang
Journal:  Curr Diab Rep       Date:  2016-11       Impact factor: 4.810

9.  Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept.

Authors:  Mayte Suárez-Fariñas; Kejal R Shah; Asifa S Haider; James G Krueger; Michelle A Lowes
Journal:  BMC Dermatol       Date:  2010-02-12

10.  Biologics in dermatologic therapy - an update.

Authors:  Arijit Coondoo
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.